Postmarketing Surveillance Study of EVENITY (Romosozumab) in South Korea (20170753)

19/07/2019
16/01/2026
EU PAS number:
EUPAS30346
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Updated protocol

Protocol-Published Superseding romosozumab 20170753 2 .pdf

First published: 07/11/2024
English (4.25 MB - PDF) View document
Study results
Study results

20170753 redacted ORSR Abstract_ final _25Nov2025.pdf

English (250.48 KB - PDF) View document
Study report
Other information